Fig. 3

ABT-263 synergized with apigenin to suppress engineered BaF3 cells harboring EGFR mutation. a Agarose gel electropherogram of plasmid of pCDH-EGFR-WT, -T790M, -L858R, -T790M/L858R, -G719S and -C797S digestion and PCR of EGFR gene cDNA ORF clone sequences. b Engineered BaF3 cells with or without EGFRm were harvested and EGFR protein levels were detected by Western blotting. c Cells were treated with increasing doses of apigenin for 2 days. Cell viability rates were examined using MTT assay (upper) and the IC50 value was calculated (lower). d Cells were seeded in 24-well plates and treated with Apg (5 µM) and ABT (0.5 µM), alone or comb for 1 day. Cell viability rates were analyzed using MTT assay. Data represent mean ± SD (n = 3). *p < 0.05, and **p < 0.01 vs single compound treatment group